Drug Profile
ADN LYS
Alternative Names: ADN-LYSLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator ADIENNE
- Class Enzymes
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gaucher's disease
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Gaucher's-disease in Switzerland
- 02 Aug 2017 Preclinical trials in Gaucher's disease in Switzerland before August 2017 (ADIENNE pipeline, August 2017)